Furthermore, treatment with 5-azacytidine (5-Aza), a DNA methyltransferase inhibitor, resulted in a significant upregulation of TRAF3 mRNA and protein levels in both patient-derived and commercially available GBM cell lines (Figure 1G and Supplemental Figure 1E). This evidence concerns the gene TRAF3 and glioblastoma.